Live News Reader

Some of the articles presented on this website are accessed through RSS feeds from third-party sources that are not necessarily part of the Histiocytosis Association. While we try to select appropriate feeds to prevent objectionable content from being displayed, the presence of any article does not indicate endorsement or recommendation by the Histiocytosis Association.

If you know of a histio-related article that isn't shown here, please send the article to outreach@histio.org.

Erdheim-Chester disease - Google News
Trovagene, Inc. Announces Second Quarter 2014 Financial Results - Wall Street Journal

Trovagene, Inc. Announces Second Quarter 2014 Financial Results
Wall Street Journal
Assay technology referenced in multi-disciplinary clinical consensus guidelines for the treatment of Erdheim-Chester disease. Highlights ability of the Company's precision cancer monitoring technology to detect actionable oncogene mutation status and ...


Thursday, August 07, 2014 4:12:56 PM

TrovaGene's (TROV) CEO Antonius Schuh on Q2 2014 Results - Earnings Call ... - Seeking Alpha (registration)

TrovaGene's (TROV) CEO Antonius Schuh on Q2 2014 Results - Earnings Call ...
Seeking Alpha (registration)
The reference to our cancer monitoring platform in international clinical treatment guidelines for histiocytic diseases such as Erdheim-Chester disease and Langerhans cell histiocytosis, and so far this year we have announced clinical collaborations ...


Saturday, August 09, 2014 5:28:16 AM

Share with Others

© Histiocytosis Association, Inc.
332 North Broadway, Pitman, New Jersey  08071 USA
Phone: +1 856-589-6606 | Fax: +1 856-589-6614
| info@histio.org
Tax ID: 22-2827069 | Privacy | DisclaimerContact Us | Site Map
Follow Me on Pinterest